*仅供医学专科东谈主士阅读参考
AACR精彩抢先看!
整理 |是橘不是桔
4月5日~10日,第115届好意思国商酌协会(AACR)年会将于好意思国圣地亚哥举行,本年的大会主题是“激勉科学•激动向上•纠正诊疗”。算作大师历史悠久的肿瘤商酌学术会议之一,AACR年会不仅聚焦肿瘤初期商酌和改革弘扬,还网罗了宽敞肿瘤界限的前沿商酌收尾。
这次AACR年会包含6场遑急整体会议标准,波及7个重心界限,设有十多个论坛和专场,并提供丰富的酬酢和职业换取平台。其中,血液界限不少重磅商酌入选了大会的理论讲演和壁报,本文特此整理重磅商酌与海报标题,供君参考!
图1 AACR官网截图
调节后劲:CAR-T细胞疗法的遑急打破
纲要号:57
Ibrutinib improves chimeric antigen receptor T cell control of leukemia by inhibiting myeloid-derived suppressor cells
伊布替尼可通过髓源性扼制细胞改善CAR-T细胞对的截至
讲演者:B. F. Frost,宾夕法尼亚大学医学院
纲要号:CT071
Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy
一种新式BCMA靶向同种异体CAR-T疗法P-BCMA-ALLO1在既往BCMA靶向养息弘扬后的复发/难治性多发性骨髓瘤(R/R MM)患者中的临床活性
讲演者:B. Dholaria,范德比尔特–英格拉姆癌症中心
纲要号:CT244
HR001,a novel CD19-targeted CAR-T cell therapy for patients with relapsed/refractory non-Hodgkin's lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)
II期HRAIN01-NHL01-II商酌的主要收尾:新式CD19靶向CAR-T细胞疗法HR001用于复发/难治性(R/R NHL)患者
讲演者:P. Liu,复旦大学附庸中山病院
纲要号:CT180
Phase I clinical trial of CD19 CAR-T cells secreting PD-1-targeting IL-21 in advanced relapsed/refractory acute lymphoblastic leukemia
CD19 CAR-T细胞分泌靶向PD-1的IL-21养息复发/难治性急性淋巴细胞白血病(R/R ALL)的Ⅰ期临床商酌
讲演者:Y. Li,中国科学院生物物理商酌所
纲要号:3849
Frontline ibrutinib-based therapy enhances CAR-T cell functions in patients with CLL: Analysis of the phase 3 randomized clinical trial ECOG-ACRIN E1912
Ⅲ期立地ECOG-ACRINE1912商酌的分析收尾:基于伊布替尼的一线养息可增强慢性淋巴细胞白血病(CLL)患者的CAR-T细胞功能
讲演者:T. N. Huynh,妙佑医疗外洋
新有筹谋探索:MDS和MM界限弘扬束缚
纲要号:CT060
Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
阿扎胞苷聚会Evorpacept养息高危(MDS)的Ⅰ期商酌收尾
讲演者:Guillermo Garcia-Manero,MD安德森癌症中心
纲要号:CT067
The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma
具有新式有用载荷的靶向BCMA抗体药物偶联物(ADC)HDP-101在复发性MM中展现精粹的初步收尾
讲演者:A. Strassz,海德堡制药公司
精确掂量与靶点打破:淋巴瘤商酌弘扬赶紧
纲要号:CT144
Safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma
HMPL-523(Syk扼制剂)在R/R淋巴瘤患者中的安全性和有用性
讲演者:P. Strati,MD安德森癌症中心
纲要号:CT145
The final results of a phase I study using velcade (bortezomib), cladribine, and rituximab (VCR) in treating elderly patient with mantle cell lymphoma
硼替佐米、克拉屈滨和利妥昔单抗(VCR)有筹谋养息老年套细胞淋巴瘤(MCL)患者的Ⅰ期商酌最终收尾
讲演者:J. J. Pu,哈佛医学院
纲要号:CT146
AZD0466 in patients with advanced non-Hodgkin lymphoma: Efficacy and safety in an open-label phase 1 trial
AZD0466在晚期非霍奇金淋巴瘤患者中的疗效和安全性:一项绽开标签I期商酌
讲演者:G. Chong,Olivia Newton-John癌症中心
纲要号:CT243
Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
ELM-2商酌的主要分析收尾:Odronextamab养息复发/难治性滤泡性淋巴瘤(R/R FL)
讲演者:G. Chong,Olivia Newton-John癌症中心
纲要号:CT245
Circulating tumor DNA and nivolumab maintenance: A pilot study in diffuse large B cell lymphoma
轮回肿瘤DNA和纳武利尤单抗保管把握于足够性大B细胞淋巴瘤(DLBCL)的初步商酌
讲演者:Nadia Khan,西雅图瑞典癌症商酌所
纲要号:3732
Peripheral pharmacodynamic activity of epcoritamab as monotherapy and in combination with rituximab + lenalidomide in patients with follicular lymphoma
Epcoritamab单药以及与利妥昔单抗+来那度胺聚会养息FL患者的外周药效学活性
讲演者:H. Si,Genmab公司
精彩资讯等你来
职守裁剪:Sheep
*医学界用功其发表履行专科、可靠,但永诀履行的准确性作念出甘心;请干系各方在选拔或以此算作决策依据时另行核查。